No price history available.
Key financial summary
Financials in PLN| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | PLNm | 328 | 443 | 415 | 424 | 508 | 584 | N/A | N/A |
| Operating profit | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | PLNm | 34 | 71 | 44 | 74 | 96 | 99 | N/A | N/A |
| EPS reported | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in PLN| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Voxel S.A. manages an extensive chain of facilities dedicated to diagnostic medical imaging. The company's offerings encompass a broad range of advanced imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and single photon emission computed tomography (SPECT). Furthermore, Voxel S.A. provides teleradiology and outsourcing solutions within the diagnostic imaging sector, alongside developing information systems specifically designed for hospitals and diagnostic centers. The firm also undertakes ventures focused on equipping and implementing new diagnostic laboratories. Established in 2005 and headquartered in Kraków, Poland, Voxel S.A. maintains its operational presence through 33 specialized laboratories situated in 21 Polish cities.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Voxel S.A. manages an extensive chain of facilities dedicated to diagnostic medical imaging. The company's offerings encompass a broad range of advanced imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and single photon emission computed tomography (SPECT). Furthermore, Voxel S.A. provides teleradiology and outsourcing solutions within the diagnostic imaging sector, alongside developing information systems specifically designed for hospitals and diagnostic centers. The firm also undertakes ventures focused on equipping and implementing new diagnostic laboratories. Established in 2005 and headquartered in Kraków, Poland, Voxel S.A. maintains its operational presence through 33 specialized laboratories situated in 21 Polish cities.